Ryaltris

Active Ingredient(s): Olopatadine Hydrochloride + Mometasone Furoate Monohydrate
FDA Approved: * January 13, 2022
Pharm Company: * GLENMARK SPECIALTY SA
Category: Allergies, Cough & Cold

Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older.[1][2][3] It contains olopatadine hydrochloride and mometasone furoate monohydrate.[1][2] It is sprayed into the nose.[1][2] Common side effects include an unpleasant ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Ryaltris Nasal Spray, Metered
NDC: 59467-700
Labeler:
Hikma Specialty USA Inc.